Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Enteric fever, an infection caused by either Salmonella typhi or Salmonella paratyphi, has been eliminated in most industrialised countries but is an increasing burden in developing countries, particularly in South East Asia. Antibiotics resistance limits safe and affordable treatment options. Training the next generation of doctors and scientists in the worst hit countries will help develop a successful and sustainable partnership.

Q: How common is enteric fever?

Christiane Dolecek: Enteric fever is common in developing countries, especially in children and young adults. We don't know the exact numbers but it is estimated that worldwide there are approximately 21 million infections per year. It causes approximately 200,000 deaths each year. This disease has been eliminated in most industrialised countries through water and sewage treatment, and education about better food hygiene. It is an infection caused by one of two bacteria: Salmonella tyhpi and Salmonella paratyphi. These bacteria are ingested through contaminated water or food and then via the gut enter the blood, causing a severe bloodstream infection. What is interesting is that this disease only infects humans so we have the possibility to eradicate it.

Q: How is enteric fever treated?

CD: Enteric fever is treated with a course of antibiotics, from several days to two weeks. We see that the bacteria have evolved and developed drug resistance so the big problem now is that the treatments that we used 5 or 10 years ago are not effective any longer. The number of treatments options that are safe and affordable is very limited.

Q: Why work on enteric fever in Asia?

CD: South East Asia has the biggest burden of enteric fever. Our research is based in Nepal, a country that has a very high burden. We work there at two major hospitals but we also have collaborations and share information and work with other hospitals in Asia and Africa, where this disease is of increasing importance.

Q: What are the most important lines of research that have developed in the last 5 or 10 years?

CD: Our work focuses on identifying the best treatment for the patient, to cure the symptoms the quickest. It also stops transmission because when a patient is sick they shed the bacteria in their stools and this is how their family members and relatives get infected. By treating the patient we can stop this part of this disease and reduce the burden of this disease. One of our major targets is to see how to use the current available antibiotics in the best way. There is also a problem with diagnostics as there are no rapid tests. In order to make the diagnosis you need a blood culture and those facilities are not available in many countries in Asia or Africa.

Q: Why does your line of research matter, why should we invest in it?

CD: Enteric fever is a neglected disease so there is no commercial interest but it is still an important disease that causes huge suffering. It is very important that the University of Oxford works where the burden is the biggest and tries to make a difference.

Q: How does your research fit into Translational Medicine within the Department?

CD: In the sense that translational medicine means that using the best science to benefit the biggest number of patients, then it is an excellent example. Our studies are based on clinical trials, so we learn from the patients. We ask very practical questions and we also train the next generation of doctors and scientists at the Oxford University Clinical Research Unit in Nepal, lead by Professor Buddha Basnyat. We hope that this is a successful and sustainable partnership and that it makes a real difference to the disease.

Note: This interview was recorded in November 2014, a few months before devastating earthquakes struck Nepal in April and May 2015.

Emergency Health Care in Nepal

The 2015 earthquakes in Nepal have caused a tragic loss of life and had a devastating impact on infrastructure. The challenges are enormous and include risks of major epidemics, particularly of water born disease.
The Oxford University Clinical Research Unit Nepal, based at Patan Hospital, focuses on enteric fever and other causes of febrile illness such as typhus and Hepatitis E.

Christiane Dolecek

Dr Christiane Dolecek's clinical research focuses on tropical diseases, in particular enteric fever and malaria. She has led enteric fever clinical trials in Vietnam and Nepal with the aim to systematically assess the current WHO recommendations as well as new treatment options.

More podcasts related to Global Health

Mike English: Health services that deliver for newborns

Basic hospital care may be key to saving newborn lives. Professor Mike English outlines a multidisciplinary project engaging policy-makers and practitioners in Kenya. This project demonstrated poor coverage of Nairobi’s 4.25 million population if a sick newborn baby needs quality hospital care. Using novel research approaches the team also identified how severe shortages of nurses contribute to poor quality of care for patients and negatively affect nurses themselves.

Tran Hien: Infectious diseases in the tropics

Although incidence of malaria has decreased in Vietnam, the burden of infectious diseases remains high and weighs heavily on the health care system. Clinical research aims to allow investments to go further: findings in the laboratory, tested in clinical trials and then applied to the community, help improve diagnosis and management.

Ronald Geskus: Sophisticated biostatistics for complex clinical research

The role of biostatisticians in clinical research is to contribute to trial design, by calculating sample size for example, and to help draw correct conclusions from the data, discriminating important information from noise. They are instrumental in the translation of a practical problem into a statistical model, and the translation of the result into practice.

Rogier Van Doorn: Research at OUCRU Hanoi

Antibiotics are widely used in Vietnam, leading to widespread antimicrobial resistance. Monitoring antibiotic use helps inform the government to change treatment guidelines and implement antibiotic stewardship programmes. This may also prevent the transmission of resistant bacteria outside the country.

Heiman Wertheim: Clinical research in low and middle-income countries

Drug resistant infections are a global crisis and we cannot focus on our own country only. Clinical trials in low and middle income countries where the burden is highest, as well as work with local communities and engagement with policy makers help influence public health policies.

Guy Thwaites: Tuberculosis meningitis

Tuberculosis meningitis affects a fractions of TB patients but causes high levels of mortality and morbidity. A recent trial at OUCRU showed that aspirin can greatly improve outcomes. Such trial is typical of the work done in our Vietnam units, where all the research is focussed on improving the outcome for patients directly.

Motiur Rahman: OUCRU laboratory management

OUCRU laboratories provide support to the unit’s extensive clinical research programme, from level 2 laboratory to SAPO 4 laboratory for high-risk pathogens responsible for zoonotic infections. Early diagnosis and detection of antimicrobial resistance helps prescribe the right medicine in time, contributing to better patient management.

Raph Hamers: Developing collaborative clinical trials in Indonesia

Indonesia is a very populous country with a huge burden of infectious diseases such as TB, malaria, HIV and CNS infections. Running clinical trials requires high levels of expertise, currently developed and strengthened by institutions such as IOCRL (Universities of Indonesia and Oxford Clinical Research laboratory). Better collaborations will also help great ideas make a bigger impact.

Jeremy Day: Central nervous system and HIV infections in Vietnam

Brain infections such as meningitis and encephalitis are highly debilitating diseases, and an accurate diagnostic is essential to give patients the best treatment available. For cryptococcal meningitis, clinical trials focus on prevention, for an early diagnosis, and novel ways to use existing treatments or repurpose old drugs.

Abhilasha Karkey: Connecting research with communities in Nepal

Antimicrobial resistance is a huge burden in Nepal, particularly in hospitals where many nosocomial infections are caused by resistant pathogens. With limited resources, little infection controls and proper guidelines in place, finding out the main risk factors helps reduce infection rates within a hospital and better target vaccination campaigns.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.